CDKN2A and acute lymphoblastic leukemia: Specific association of this deletion with a particular subgroup with a marked prognosis impact (e.g., non-ETP-ALL and the Ph-like group) could be behind the contrasting clinical impacts of CDKN2A/B deletions in the BCP and T-ALL subtypes in general.